Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Evolocumab · Repatha, AMG-145

Monoclonal antibody · Inhibitor of PCSK9 · developed by Amgen

Approved FDA, Aug 2015
AMGN Developer
1 Registered trials

What is Evolocumab?

Evolocumab is a human monoclonal IgG2 antibody that inhibits PCSK9, a protein that promotes degradation of the LDL receptor on hepatocytes. By blocking PCSK9 binding to the LDL receptor, evolocumab increases LDL receptor availability to clear LDL cholesterol from the blood, thereby lowering LDL-C levels and reducing cardiovascular risk.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Repatha, AMG-145
Drug type
Monoclonal antibody
Targets
PCSK9, LDLR (secondary target)
Mechanism
Inhibitor of PCSK9
Pathways
LDL clearance, cholesterol metabolism
Therapy area
Cardiovascular
Developer
Amgen Inc (AMGN)
FDA status
Approved as Repatha (August 27, 2015), BLA125522 · FDA label
UNII
LKC0U3A8NJ

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 19, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07803679 Phase 4 Coronary Artery Disease Not yet recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AtheromaAtherosclerotic PlaqueCoronary Artery DiseaseHypercholesterolemia

Other drugs acting on PCSK9

Enlicitide FDA approved Lerodalcibep FDA approved

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Evolocumab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.